Journal: Neural Regeneration Research

Article Title: 5-O-Methylvisammioside alleviates depression-like behaviors by inhibiting nuclear factor kappa B pathway activation via targeting SRC

doi: 10.4103/NRR.NRR-D-24-00714

Figure Lengend Snippet: Experimental overview. (A) Mice were pretreated with MeV and Flu for 11 days before administration of LPS for 3 days to establish the LPS-induced depression model. Flu, an antidepressant, served as the positive control ( n = 14). (B) In the second experiment, the SRC inhibitor PP2 was administered to the indicated groups by intraperitoneal injections for 14 days with LPS model establishment as described above. At the end of treatment, the mice underwent behavioral tests and were subsequently euthanized. Whole brain tissue, hippocampus, and serum were collected ( n = 20). ALB: Albumin; Flu: fluoxetine; FST: forced swimming test; IF: immunofluorescence; LPS: lipopolysaccharide; MeV: 5-O-methylvisammioside; OFT: open field test; SPT: sucrose preference test; TST: tail suspension test; WB: Western blot.

Article Snippet: Saline, MeV (4 mg/kg per day; RS00021020, Nature-standard, Shanghai, China), Flu (10 mg/kg per day; PHR1394-1g, Sigma Aldrich), and PP2 (2.5 mg/kg per day; HY-13805, MedChemExpress, Monmouth Junction, NJ, USA) were administered via intraperitoneal injection using a 1 mL syringe on days 1–14.

Techniques: Positive Control, Immunofluorescence, Suspension, Western Blot

Journal: Neural Regeneration Research

Article Title: 5-O-Methylvisammioside alleviates depression-like behaviors by inhibiting nuclear factor kappa B pathway activation via targeting SRC

doi: 10.4103/NRR.NRR-D-24-00714

Figure Lengend Snippet: Effects of SRC inhibition on NF-κB pathway protein expression and depression-like behaviors in mice with LPS-treated. (A–H) Representative blots of TLR4, p-NF-κB, NF-κB, IκBα, IL1β, p-SRC, and SRC and quantification of protein expressions ( n = 3–6). (I, J) Results from the open field test (OFT) ( n = 10). (K) Results from the tail suspension test ( n = 10). (L) Results from the forced swimming test ( n = 9). (M) Results from the sucrose preference test ( n = 8). (N) Serum ALB levels in mice ( n = 6). Data are presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way analysis of variance followed by Tukey’s post hoc test). ALB: Albumin; IBA1: ionized calcium-binding adapter molecule 1; IκBα: inhibitory subunit of NF-κB alpha; IL1β: interleukin 1 beta; LPS: lipopolysaccharide; NF-κB: nuclear factor kappa B; ns: not significant; p-NF-κB: phospho-NF-κB; PP2: SRC inhibitor; SRC: non-receptor tyrosine kinase Src; p-SRC: phospho-SRC; TLR4: Toll-like receptor 4.

Article Snippet: Saline, MeV (4 mg/kg per day; RS00021020, Nature-standard, Shanghai, China), Flu (10 mg/kg per day; PHR1394-1g, Sigma Aldrich), and PP2 (2.5 mg/kg per day; HY-13805, MedChemExpress, Monmouth Junction, NJ, USA) were administered via intraperitoneal injection using a 1 mL syringe on days 1–14.

Techniques: Inhibition, Expressing, Suspension, Binding Assay

Journal: Neural Regeneration Research

Article Title: 5-O-Methylvisammioside alleviates depression-like behaviors by inhibiting nuclear factor kappa B pathway activation via targeting SRC

doi: 10.4103/NRR.NRR-D-24-00714

Figure Lengend Snippet: Effects of MeV treatment on microglial activation in mice with LPS-induced depression. (A, B) Representative western blot images showing IBA1 expression and quantification of protein expression ( n = 6). (C, D) Representative fluorescence images of IBA1 (green) in the hippocampal CA1 and CA3 regions and quantification of relative intensity ( n = 3). Scale bars: 200 µm. Data are presented as mean ± SEM. * P < 0.05, ** P < 0.01 (one-way analysis of variance followed by Tukey’s post hoc test). CA: Cornu ammonis; IBA1: ionized calcium-binding adapter molecule 1; LPS: lipopolysaccharide; MeV: 5-O-methylvisammioside; PP2: SRC inhibitor.

Article Snippet: Saline, MeV (4 mg/kg per day; RS00021020, Nature-standard, Shanghai, China), Flu (10 mg/kg per day; PHR1394-1g, Sigma Aldrich), and PP2 (2.5 mg/kg per day; HY-13805, MedChemExpress, Monmouth Junction, NJ, USA) were administered via intraperitoneal injection using a 1 mL syringe on days 1–14.

Techniques: Activation Assay, Western Blot, Expressing, Fluorescence, Binding Assay